Press Release: Novartis Fabhalta(R) (iptacopan) -2-

of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com/ https://www.novartis.com and connect with us on https://www.linkedin.com/company/novartis/ LinkedIn, https://www.facebook.com/novartis/ Facebook, https://twitter.com/Novartis X/Twitter and https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$ Instagram.

References

1. Committee for Medicinal Products for Human Use (CHMP). Available at

https://www.ema.europa.eu/en/committees/committee-medicinal-products-human-use-chmp.

Accessed March 2024.

2. Ristanio AM, R th A, Kulasekararaj A, et al. Oral Iptacopan Monotherapy

Has Superior Efficacy to Anti-C5 Therapy in Patients with Paroxysmal

Nocturnal Hemoglobinuria and Residual Anemia. Results from the Phase III

APPLY-PNH Study. Presented at 49th Annual Meeting of the European Society

for Blood and Marrow Transplantation (EBMT); April 23-26, 2023; Paris,

France.

3. Risitano AM, Han B, Ueda Y, et al. Oral Complement Factor B Inhibitor

Iptacopan Monotherapy Improves Hemoglobin to Normal/Near-Normal Levels in

Paroxysmal Nocturnal Hemoglobinuria Patients Naïve to Complement

Inhibitors: Phase III APPOINT-PNH Trial. Presented at: 49th Annual

Meeting of the European Society for Blood and Marrow Transplantation

(EBMT); April 23-36, 2023; Paris, France.

4. Risitano AM, Röth A, Soret J, et al. Addition of iptacopan, an oral

factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal

haemoglobinuria and active haemolysis: an open-label, single-arm, phase

2, proof-of-concept trial. Lancet Haematol. 2021;8(5):e344-e354.

doi:10.1016/S2352-3026(21)00028-4

5. Jang JH, Wong L, Ko BS, et al. Iptacopan monotherapy in patients with

paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label

proof-of-concept study. Blood Adv. 2022;6(15):4450-4460.

doi:10.1182/bloodadvances.2022006960

6. McKinley CE, Richards SJ, Munir T, et al. Extravascular Hemolysis Due to

C3-Loading in Patients with PNH Treated with Eculizumab: Defining the

Clinical Syndrome. Blood. 2017;130(Supplement 1):3471.

doi:10.1182/blood.V130.Suppl_1.3471.3471

7. Dingli D, Matos JE, Lehrhaupt K, et al. The burden of illness in patients

with paroxysmal nocturnal hemoglobinuria receiving treatment with the

C5-inhibitors eculizumab or ravulizumab: results from a US patient

survey. Ann Hematol. 2022;101(2):251-263. doi:10.1007/s00277-021-04715-5

8. Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal

haemoglobinuria Nat Rev Dis Primers.

2017;3:17028. doi:10.1038/nrdp.2017.28

9. Shah N, Bhatt H. Paroxysmal Nocturnal Hemoglobinuria. In:

StatPearls.Treasure Island (FL): StatPearls Publishing; 2023 Jan.

10. Brodsky RA. Paroxysmal Nocturnal Hemoglobinuria. Blood.

2014;124(18):2804-2811. doi:10.1182/blood-2014-02-522128

11. Schrezenmeier H, Muus P, Socié G, et al. Baseline characteristics

and disease burden in patients in the International Paroxysmal Nocturnal

Hemoglobinuria Registry. Haematologica.

2014;99(5):922-929. doi:10.3324/haematol.2013.093161

12. Cançado RD, Araújo A da S, Sandes AF, et al. Consensus

statement for diagnosis and treatment of paroxysmal nocturnal

haemoglobinuria. Hematol Transfus Cell Ther. 2021;43(3):341-348.

doi:10.1016/j.htct.2020.06.006

13. Risitano AM, Marotta S, Ricci P, et al. Anti-complement Treatment for

Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement

Inhibition? A Position Paper From the SAAWP of the EBMT. Front Immunol

2019;10:1157. doi:10.3389/fimmu.2019.01157

14. Shammo et al. HemaSphere 2023 Shammo J, Kim J, Georget M, et al. P796:

Hospitalization in patients with paroxysmal nocturnal hemoglobinuria: a

retrospective analysis of observational study data from the United

States. Hemasphere. 2023;7(Suppl ):e22585a2.

doi:10.1097/01.HS9.0000970088.22585.a2

15. Debureaux PE, Kulasekararaj AG, Cacace F, et al. Categorizing

hematological response to eculizumab in paroxysmal nocturnal

hemoglobinuria: a multicenter real-life study. Bone Marrow Transplant.

2021;56(10):2600-2602. doi:10.1038/s41409-021-01372-0

16. Schrezenmeier H, Kulasekararaj A, Mitchell L, et al. One-year efficacy

and safety of ravulizumab in adults with paroxysmal nocturnal

hemoglobinuria naïve to complement inhibitor therapy: open-label

extension of a randomized study. Ther Adv Hematol.

2020;11:2040620720966137. doi:10.1177/2040620720966137

17. Young NS, Meyers G, Schrezenmeier H, Hillmen P, Hill A. The management of

paroxysmal nocturnal hemoglobinuria: recent advances in diagnosis and

treatment and new hope for patients. Semin Hematol. 2009;46(1 Suppl

1):S1-S16. doi:10.1053/j.seminhematol.2008.11.004

18. Novartis. Data on file

19. Risitano AM, Kulasekararaj A, R th A, et al. Factor B Inhibition with

Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and

Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal

Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from

the Multicenter, Phase III APPLY-PNH Trial. Presented at: 65th American

Society of Hematology Annual Meeting & Exposition (ASH); December 9-12,

2023; San Diego, CA.

20. Novartis Pharmaceuticals. A Randomized, Multicenter, Active-Comparator

Controlled, Open-Label Trial to Evaluate Efficacy and Safety of Oral,

Twice Daily LNP023 in Adult Patients With PNH and Residual Anemia,

Despite Treatment With an Intravenous Anti-C5 Antibody.

clinicaltrials.gov. Accessed February 14, 2024.

https://clinicaltrials.gov/ct2/show/NCT04558918

21. Novartis Pharmaceuticals. A Multicenter, Single-Arm, Open-Label Trial to

Evaluate Efficacy and Safety of Oral, Twice Daily Iptacopan in Adult PNH

Patients Who Are Naive to Complement Inhibitor Therapy.

clinicaltrials.gov. Accessed February 14, 2024.

https://clinicaltrials.gov/ct2/show/NCT04820530

22. Schrezenmeier H, Röth A, Araten DJ, et al. Baseline clinical

characteristics and disease burden in patients with paroxysmal nocturnal

hemoglobinuria (PNH): updated analysis from the International PNH

Registry. Ann Hematol. 2020;99(7):1505-1514.

doi:10.1007/s00277-020-04052-z

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Central North America

Richard Jarvis +41 79 584 2326 Julie Masow +1 862 579 8456

Anja von Treskow +41 79 392 9697 Michael Meo +1 862 274 5414

Anna Schäfers +41 79 801 7267 Marlena Abdinoor +1 617 335 9525

Switzerland

Satoshi Sugimoto +41 79 619 2035

Novartis Investor Relations

Central investor relations line:

+41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Isabella Zinck +41 61 324 7188 Jonathan Graham +1 201 602 9921

Nicole Zinsli-Somm +41 61 324 3809 Parag Mahanti +1 973 876 4912

Imke Kappes +41 61 324 8269

(END) Dow Jones Newswires

March 22, 2024 07:22 ET (11:22 GMT)